Inflammasome Therapeutics’ K8 Implant Cuts Lesion Growth by more than 50% in Geographic Atrophy after Three Months in Multi-Center Trial

NEWTON, Mass.--(BUSINESS WIRE)-- #NRTIs--Inflammasome Therapeutics (https://www.inflam.com), is a clinical-stage biotech company developing a new class of inflammasome inhibitors called Kamuvudines for ophthalmic and neurological conditions. Today, the company announced that the first of these drugs, K8, delivered via a sustained release intraocular implant for the treatment of Geographic Atrophy (GA), reduced GA lesion area growth by more than 50% following three months of treatment among an initial co